Transgene Toekomstige groei
Future criteriumcontroles 2/6
De verwachting is dat Transgene de winst en omzet met respectievelijk 3.3% en 76.1% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 24.2% per jaar.
Belangrijke informatie
3.3%
Groei van de winst
24.18%
Groei van de winst per aandeel
| Biotechs winstgroei | 58.4% |
| Inkomstengroei | 76.1% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 30 Apr 2026 |
Recente toekomstige groei-updates
Recent updates
Narratiefupdate • Jun 05
TNG: Phase II Head And Neck Data Will Drive Future Repricing
Analysts have adjusted their fair value estimate for Transgene stock to €1.10 per share. This change reflects updated assumptions on discount rates, profit margins and a significantly higher future P/E multiple in their models.Narratiefupdate • Apr 23
TNG: Phase II Head And Neck Progress Will Drive Future Repricing
Analysts have kept their price target for Transgene broadly steady at €1.10, citing updated assumptions around discount rates, profit margins and future P/E that refine rather than overhaul their valuation view. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed €1.10 target as a signal that core valuation inputs such as discount rates and profit assumptions still support the current framework rather than requiring a reset.Narratiefupdate • Apr 09
TNG: Phase I Head And Neck Data Will Support Future Repricing
Analysts have adjusted their price target on Transgene to €1.10, based on updated assumptions that include a very large change in revenue growth expectations, a lower discount rate, and a revised future P/E of about 13x. Analyst Commentary Bullish Takeaways Bullish analysts view the revised €1.10 price target and the use of a P/E of about 13x as a sign that current assumptions aim to better align valuation with the risk profile investors are willing to accept.Narratiefupdate • Mar 25
TNG: Phase I Head And Neck Data Will Drive Future Repricing
Analysts have kept their price target on Transgene broadly in line with prior views, with only marginal tweaks to inputs like the discount rate and long term P/E assumptions, indicating a steady valuation framework in euro terms rather than a meaningful reset. What's in the News Transgene released a preprint on medRxiv covering clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic cancer vaccine for operable head and neck cancers (medRxiv).Narratiefupdate • Mar 11
TNG: Phase I Head And Neck Vaccine Data Will Support Future Repricing
Analysts have maintained their price target for Transgene at €1.10, reflecting largely stable assumptions on the discount rate, revenue trends, margins, and future P/E expectations. What's in the News Transgene released a preprint on medRxiv with a comprehensive analysis of clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine.Narratiefupdate • Feb 24
TNG: Phase I Head And Neck Data Will Drive Future Repricing
Analysts have reduced their price target for Transgene to €1.10 from €2.00, reflecting updated assumptions that include a higher discount rate, lower revenue growth expectations, improved profit margin and a lower future P/E multiple. What's in the News Transgene released a preprint on medRxiv detailing clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine for operable head and neck cancers (medRxiv preprint).
Narratiefupdate • Feb 10
TNG: Individualized Cancer Vaccine Platform Will Drive Future Upside Potential
Analysts have adjusted their price target on Transgene slightly, reflecting updated assumptions for a discount rate, revenue growth of 33.57% and a forward P/E of 27.97x, while keeping fair value at €1.10. This suggests a more finely tuned view of the company’s risk and earnings profile rather than a major shift in outlook.Narratiefupdate • Jan 26
TNG: Individualized Cancer Vaccine Platform Will Drive Future Upside Potential
Analysts have adjusted their price target for Transgene, citing updated assumptions on discount rate, revenue growth, profit margin and a lower future P/E multiple as key drivers of the change in valuation. The new target is presented in line with a fair value estimate of €1.10 per share.Narratiefupdate • Jan 12
TNG: Clinical Progress And Capital Raise Will Support Future Upside
Analysts have adjusted their price target for Transgene, citing updated assumptions that keep fair value at €1.10 while reflecting different views on revenue growth, profit margins, and a higher future P/E multiple. What's in the News Preprint publication on medRxiv shares clinical and translational data from the Phase I part of Transgene's randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine, with the manuscript also submitted to a peer reviewed journal for evaluation (Product related announcement).Narratiefupdate • Dec 14
TNG: Pipeline Progress And Stronger Balance Sheet Will Drive Future Upside
Analysts have moderately reduced their price target on Transgene, cutting fair value by about 20 percent to approximately 1.10 euros. They have incorporated slower expected revenue growth, a higher discount rate, and a more balanced, though significantly improved, long term profit margin outlook into their models.Analyseartikel • May 27
Is Transgene (EPA:TNG) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Nieuw narratief • Apr 07
TG4050 Trial And Pipeline Developments Will Transform Cancer Vaccines
Progress in TG4050 trials could establish Transgene as a leader in cancer vaccines, boosting reputation and revenue opportunities.Analyseartikel • Jun 15
Is Transgene (EPA:TNG) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analyseartikel • Mar 21
Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term
One thing we could say about the analysts on Transgene SA ( EPA:TNG ) - they aren't optimistic, having just made a...Analyseartikel • Mar 19
Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Last week, you might have seen that Transgene SA ( EPA:TNG ) released its full-year result to the market. The early...Analyseartikel • Mar 18
Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Nov 24
Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Apr 16
Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Mar 12
What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?
Every investor in Transgene SA ( EPA:TNG ) should be aware of the most powerful shareholder groups. Insiders often own...Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 57 | -25 | -25 | -18 | 1 |
| 12/31/2027 | 7 | -62 | -60 | -59 | 1 |
| 12/31/2026 | 7 | -38 | -40 | -39 | 1 |
| 12/31/2025 | 7 | -38 | -38 | -37 | N/A |
| 9/30/2025 | 7 | -37 | -31 | -30 | N/A |
| 6/30/2025 | 8 | -37 | -24 | -23 | N/A |
| 3/31/2025 | 7 | -35 | -25 | -23 | N/A |
| 12/31/2024 | 6 | -34 | -27 | -24 | N/A |
| 9/30/2024 | 6 | -28 | -33 | -30 | N/A |
| 6/30/2024 | 6 | -23 | -39 | -36 | N/A |
| 3/31/2024 | 7 | -23 | -38 | -35 | N/A |
| 12/31/2023 | 8 | -22 | -37 | -35 | N/A |
| 9/30/2023 | 8 | -28 | -36 | -34 | N/A |
| 6/30/2023 | 9 | -33 | -35 | -33 | N/A |
| 3/31/2023 | 10 | -33 | -28 | -26 | N/A |
| 12/31/2022 | 10 | -33 | -22 | -20 | N/A |
| 9/30/2022 | 14 | -28 | -18 | -17 | N/A |
| 6/30/2022 | 18 | -23 | -15 | -15 | N/A |
| 3/31/2022 | 18 | -21 | -21 | -20 | N/A |
| 12/31/2021 | 17 | -20 | -27 | -26 | N/A |
| 9/30/2021 | 13 | -23 | -29 | -28 | N/A |
| 6/30/2021 | 9 | -27 | -31 | -30 | N/A |
| 3/31/2021 | 9 | -22 | -30 | -29 | N/A |
| 12/31/2020 | 10 | -17 | -30 | -29 | N/A |
| 9/30/2020 | 12 | -11 | -31 | -30 | N/A |
| 6/30/2020 | 14 | -6 | -33 | -31 | N/A |
| 3/31/2020 | 14 | -12 | -28 | -27 | N/A |
| 12/31/2019 | 13 | -19 | -24 | -22 | N/A |
| 9/30/2019 | 11 | -6 | N/A | -23 | N/A |
| 6/30/2019 | 8 | 8 | N/A | -23 | N/A |
| 3/31/2019 | 8 | 8 | N/A | -25 | N/A |
| 12/31/2018 | 7 | 8 | N/A | -28 | N/A |
| 9/30/2018 | 7 | -10 | N/A | -29 | N/A |
| 6/30/2018 | 7 | -29 | N/A | -30 | N/A |
| 3/31/2018 | 7 | -31 | N/A | -33 | N/A |
| 12/31/2017 | 7 | -32 | N/A | -35 | N/A |
| 9/30/2017 | 8 | -32 | N/A | -36 | N/A |
| 6/30/2017 | 9 | -31 | N/A | -37 | N/A |
| 3/31/2017 | 9 | -28 | N/A | -35 | N/A |
| 12/31/2016 | 10 | -24 | N/A | -34 | N/A |
| 9/30/2016 | 10 | -26 | N/A | -37 | N/A |
| 6/30/2016 | 9 | -28 | N/A | -40 | N/A |
| 3/31/2016 | 9 | -33 | N/A | -43 | N/A |
| 12/31/2015 | 10 | -38 | N/A | -45 | N/A |
| 9/30/2015 | 10 | -40 | N/A | -48 | N/A |
| 6/30/2015 | 10 | -42 | N/A | -50 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat TNG de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat TNG de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat TNG de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van TNG ( 76.1% per jaar) zal naar verwachting sneller groeien dan de markt French ( 5.7% per jaar).
Hoge groei-inkomsten: De omzet van TNG ( 76.1% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van TNG naar verwachting over 3 jaar hoog zal zijn
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/17 02:06 |
| Aandelenkoers aan het einde van de dag | 2026/06/17 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Transgene SA wordt gevolgd door 5 analisten. 1 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Arsene Guekam | CIC Market Solutions (ESN) |
| Michael Thomas Cooper | Edison Investment Research |
| Martial Descoutures | ODDO BHF Corporate & Markets |